Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa: The ACACIA Study

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Combination of Two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living With HIV-1 in Sub-Saharan Africa: The ACACIA Study

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ACACIA

Most Recent Events

  • 21 Jan 2025 According to an AIDS Clinical Trials Group media release, ACACIA is open to select ACTG sites in Botswana, Malawi, South Africa, and Zimbabwe. It is sponsored by the National Institute of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG). The study is co-funded by the Bill & Melinda Gates Foundation.
  • 21 Jan 2025 According to an AIDS Clinical Trials Group media release, the company announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also known as A5417.
  • 20 Jan 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top